Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 219.00 INR
Change Today +19.00 / 9.50%
Volume 100.0
RCN On Other Exchanges
Symbol
Exchange
Mumbai
As of 6:00 AM 03/30/15 All times are local (Market data is delayed by at least 15 minutes).

wintac ltd (RCN) Snapshot

Open
219.00
Previous Close
200.00
Day High
219.00
Day Low
219.00
52 Week High
02/5/15 - 297.00
52 Week Low
04/23/14 - 81.35
Market Cap
2.2B
Average Volume 10 Days
623.0
EPS TTM
-6.98
Shares Outstanding
10.0M
EX-Date
12/3/02
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for WINTAC LTD (RCN)

Related News

No related news articles were found.

wintac ltd (RCN) Related Businessweek News

No Related Businessweek News Found

wintac ltd (RCN) Details

Wintac Limited develops, manufactures, and markets pharmaceutical formulations in India and internationally. It offers opthalmic products, such as anti-glaucoma, anti-cholinergic, artificial tear, NSAIDs, steroids and combinations, anti infective, anti-allergic, and decongestant. The company also provides injectable products, including NSAIDs, calcium supplements, anti-emetic, analgesic, antimalarial, anesthetic, anti-infective, antimuscarinic, diuretic, cardiovascular, antihistamine, and iron supplement products. In addition, it offers critical care products comprising anticancer, antifungal, corticosteroid, cardiovascular, and supportive therapy products. Wintac Limited was incorporated in 1990 and is based in Bengaluru, India.

Founded in 1990

wintac ltd (RCN) Top Compensated Officers

Managing Director and Director
Total Annual Compensation: 2.0M
Compensation as of Fiscal Year 2014.

wintac ltd (RCN) Key Developments

Wintac Limited Announces Unaudited Standalone Earnings Results for the Third Quarter and Nine Months Ended December 31, 2014

Wintac Limited announced unaudited standalone earnings results for the third quarter and nine months ended December 31, 2014. For the quarter, the company announced net sales or income from operations, net of excise duty of INR 43.985 million compared to INR 86.734 million a year ago. Loss from operations before other income, finance costs and exceptional items were INR 31.554 million compared to profit from operations before other income, finance costs and exceptional items of INR 9.820 million a year ago. Loss from ordinary activities before tax was INR 31.591 million compared to profit from ordinary activities before tax of INR 0.668 million a year ago. Net loss was INR 18.458 million or INR 1.84 per basic and diluted share after extraordinary items compared to net profit of INR 0.668 million or INR 0.07 per basic and diluted share before and after extraordinary items a year ago. For the first nine months, the company announced net sales or income from operations, net of excise duty of INR 221.240 million compared to INR 205.042 million a year ago. Loss from operations before other income, finance costs and exceptional items were INR 33.131 million compared to INR 36.104 million a year ago. Loss from ordinary activities before tax was INR 33.248 million compared to INR 37.940 million a year ago. Net loss was INR 20.115 million or INR 2.01 per basic and diluted share after extraordinary items compared to INR 37.940 million or INR 3.78 per basic and diluted share before and after extraordinary items a year ago.

Wintac Ltd., Board Meeting, Jan 31, 2015

Wintac Ltd., Board Meeting, Jan 31, 2015. Agenda: To consider quarterly results; and to consider and approve the issue price of INR 34.90 per equity share of INRn 10 per share (Face value INR 10 plus Share premium of INR 24.90 per share) for the proposed rights Issue of equity Shares of the company.

Wintac Ltd., Board Meeting, Nov 27, 2014

Wintac Ltd., Board Meeting, Nov 27, 2014. Agenda: To consider to hive-off trade marks and marketing division for the marketing of the oncology products in order to have complete focus on the core activity of product development and manufacturing activity for the regulated export markets.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RCN:IN 219.00 INR +19.00

RCN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RCN.
View Industry Companies
 

Industry Analysis

RCN

Industry Average

Valuation RCN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 6.2x
Price/Book 5.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 6.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact WINTAC LTD, please visit www.wintaclimited.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.